Evidence map›Paper›PMID 34564169›Full record

ArticleMarine drugs2021

RSK1 vs. RSK2 Inhibitory Activity of the Marine β-Carboline Alkaloid Manzamine A: A Biochemical, Cervical Cancer Protein Expression, and Computational Study.

Alejandro M S Mayer, Mary L Hall, Joseph Lach, Jonathan Clifford, Kevin Chandrasena, Caitlin Canton, Maria Kontoyianni, Yeun-Mun Choo, Dev Karan, Mark T Hamann

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors.Journal of chemical information and modeling · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Recent advances and limitations in the application of kahalalides for the control of cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Alejandro M S MayerDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.ORCID 0000-0002-8358-4528
Mary L HallDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
Joseph LachDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.ORCID 0000-0002-0161-0631
Jonathan CliffordDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
Kevin ChandrasenaDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
Caitlin CantonDepartment of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
Maria KontoyianniDepartment of Pharmaceutical Sciences, Southern Illinois University Edwardsville, Edwardsville, IL 62026, USA.
Yeun-Mun ChooDepartment of Chemistry, University of Malaya, Kuala Lumpur 50603, Malaysia.ORCID 0000-0001-9891-5898
Dev KaranDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-0905-0886
Mark T HamannDepartment of Drug Discovery and Biomedical Sciences and Public Health, Colleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Midwestern University · USMedical College of Wisconsin · USMedical University of South Carolina · USSouthern Illinois University Edwardsville · USUniversity of Malaya · MY

Funding

Natural Product HCV Drugs from Rare Plant-Microbe InteractionsR01AT007318 · NCCIH · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2012 to 2016
$1.6M
Midwestern University Not ApplicableNCCIH NIH HHS R01 AT007318
6 · The paper itself

Abstract

Manzamines are complex polycyclic marine-derived β-carboline alkaloids with reported anticancer, immunostimulatory, anti-inflammatory, antibacterial, antiviral, antimalarial, neuritogenic, hyperlipidemia, and atherosclerosis suppression bioactivities, putatively associated with inhibition of glycogen synthase kinase-3, cyclin-dependent kinase 5, SIX1, and vacuolar ATPases. We hypothesized that additional, yet undiscovered molecular targets might be associated with Manzamine A's (MZA) reported pharmacological properties. We report here, for the first time, that MZA selectively inhibited a 90 kDa ribosomal protein kinase S6 (RSK1) when screened against a panel of 30 protein kinases, while in vitro RSK kinase assays demonstrated a 10-fold selectivity in the potency of MZA against RSK1 versus RSK2. The effect of MZA on inhibiting cellular RSK1 and RSK2 protein expression was validated in SiHa and CaSki human cervical carcinoma cell lines. MZA's differential binding and selectivity toward the two isoforms was also supported by computational docking experiments. Specifically, the RSK1-MZA (N- and C-termini) complexes appear to have stronger interactions and preferable energetics contrary to the RSK2-MZA ones. In addition, our computational strategy suggests that MZA binds to the N-terminal kinase domain of RSK1 rather than the C-terminal domain. RSK is a vertebrate family of cytosolic serine-threonine kinases that act downstream of the ras-ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway, which phosphorylates substrates shown to regulate several cellular processes, including growth, survival, and proliferation. Consequently, our findings have led us to hypothesize that MZA and the currently known manzamine-type alkaloids isolated from several sponge genera may have novel pharmacological properties with unique molecular targets, and MZA provides a new tool for chemical-biology studies involving RSK1.

Indexed as

PoriferaAnimalsAntineoplastic AgentsAquatic OrganismsCarbazolesFemaleHumansMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 3Molecular Docking SimulationUterine Cervical NeoplasmsAntineoplastic AgentsCarbazolesmanzamine AMitogen-Activated Protein Kinase 390 kDa ribosomal protein S6 kinase 190 kDa ribosomal protein S6 kinase 2C-terminal kinase domainCTKDManzamine AMZAN-terminal kinase domainNTKDras-ERK1/2 (extracellular-signal-regulated kinase 1/2) pathwayRSK1RSK2

Identifiers

PMID34564169
PMCPMC8467814
OpenAlexW3197137288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.